Get the Stockscreener App
1.46
0.68%
-0.01
After Hours:
1.39
-0.07
-4.79%
Bone Biologics Corp stock is traded at $1.46, with a volume of 465.86K.
It is down -0.68% in the last 24 hours and up +16.80% over the past month.
Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.
See More
Previous Close:
$1.47
Open:
$1.53
24h Volume:
465.86K
Relative Volume:
10.88
Market Cap:
$2.62M
Revenue:
-
Net Income/Loss:
$-2.86M
P/E Ratio:
-0.5823
EPS:
-2.5071
Net Cash Flow:
$-2.57M
1W Performance:
+14.96%
1M Performance:
+16.80%
6M Performance:
-21.38%
1Y Performance:
-72.45%
1-Day Range:
$1.36
$1.53
1-Week Range:
$1.22
$1.54
52-Week Range:
$1.05
$6.75
Bone Biologics Corp Stock (BBLG) Company Profile
Name
Bone Biologics Corp
Sector
Industry
Phone
(781) 552-4452
Address
2 BURLINGTON WOODS DRIVE,, BURLINGTON
Compare BBLG vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBLG
Bone Biologics Corp
|
1.46 | 2.62M | 0 | -2.86M | -2.57M | -2.5071 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bone Biologics Corp Stock (BBLG) Latest News
Bone Biologics Corp (BBLG) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bone Biologics Corp (BBLG) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bone Biologics Corp (BBLG) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bone Biologics Corp (BBLG) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bone Biologics Corp (BBLG) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bone Biologics Corp (BBLG) Valuation: PE, PB & Fair Value Analysis - TradingKey
Bone Biologics Corp (BBLG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bone Biologics Corp (BBLG) Institutional Confidence - TradingKey
Bone Biologics Corp (BBLG) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bone Biologics Corp (BBLGW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bone Biologics Corp (BBLGW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bone Biologics Corp (BBLGW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bone Biologics Corp (BBLGW) Institutional Confidence - TradingKey
Bone Biologics Corp (BBLGW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Bone Biologics Corp (BBLGW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bone Biologics Corp (BBLGW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BBLG Q1 2026 Earnings: Narrower-than-Expected Loss Offers Some Relief as Pipeline Progress ContinuesEPS Estimate Trend - newsline.com
Bone Biologics Corp (BBLGW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BBLG | Bone Biologics Corp Common Insider Trading - Quiver Quantitative
BBLG Q1 2026 Earnings: EPS Beat on Narrower Loss, Stock Dips SlightlyDiluted EPS Report - newsline.com
Bone Biologics Corp (BBLG) Edges Lower Amid Light Trading – Key Support Level in FocusBreadth Thrust - newsline.com
Bone Biologics Corp (BBLG) Edges Lower in Quiet Trading, Holding Above $1.19 SupportBear Flag - newsline.com
Bone Biologics Corp Warrants (BBLGW) Remains Steady at $14.0, Navigating Key Support and Resistance LevelsEnding Diagonal - newsline.com
Bone Biologics Corp Warrants (BBLGW) Surge Over 9%: Key Levels and OutlookOBV Trend Line - newsline.com
Why Marvell Technology Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket - Benzinga
Asia Demineralized Bone Matrix Allograft MaterialsMarket Analysis, Forecast, Size, Trends and Insights - IndexBox
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
BBLG Q1 2026 Earnings: Narrower-than-Expected Loss Per ShareRevenue Miss Report - newsline.com
Bone Biologics Corp (BBLG) Edges Higher as Stock Tests Key Technical LevelsATR Stop - newsline.com
NUWE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
World Demineralized bone matrix allograft materialsMarket Analysis, Forecast, Size, Trends and Insights - IndexBox
BBLG Q1 2026 Earnings: Smaller-than-Expected Loss on No Revenue as Bone Graft Developer Continues R&D ProgressGAAP Earnings Report - The Legal Advocate
BBLG Q1 2026 Earnings: Narrower Loss Surprises as Bone Biologics Advances Pre-Clinical PipelineEarnings Recovery Stocks - newsline.com
Bone Biologics Corp (BBLG) Surges 5.24% — Can It Hold Above Key Resistance?Factor Rotation - The Legal Advocate
Bone Biologics Corp (BBLG) Tests Support After Marginal DeclineSize Factor - newsline.com
Bone Biologics Corp (BBLG) Rises 3.28% as Stock Approaches Resistance LevelFundamental Weighted - The Legal Advocate
Bone Biologics Corp Warrants (BBLGW) Holding Steady at $14.15 After a Flat SessionBullish Pattern Stocks - The Legal Advocate
World Bone Graft SubstitutesMarket Analysis, Forecast, Size, Trends and Insights - IndexBox
BBLG Q1 2026 Earnings: Narrower-than-Expected Loss as Company Advances Bone Graft PlatformROIC Trend Report - Newser
BBLG Q1 2026 Earnings: Narrowed Loss Beats Estimates as Bone Biologics Advances PipelineBook Value Growth - The Legal Advocate
BBLG Q1 2026 Earnings: EPS Surprises to the Upside Despite No Revenue; Stock DeclinesAI Trading Community - Newser
Bone Biologics Corp (BBLG) Q1 2026 Earnings: Narrower Loss Beats Estimates, Shares DipSocial Signal Watchlist - Newser
BBLG Q1 2026 Earnings: Narrower-than-Expected Loss as Bone Biologics Advances DevelopmentFree Stock Community - Newser
Bone Biologics extends rhNELL-1 protein shelf life to 29 months - Investing.com
Spine fusion protein from Bone Biologics now lasts 29 months - Stock Titan
Bone Biologics Achieves 29-Month Validated Shelf Life for rhNELL-1 - Yahoo Finance
VBIO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
VBIO PE Ratio & Valuation, Is VBIO Overvalued - Intellectia AI
Bone Biologics (BBLG) flags going concern, cash runway into Q4 2026 - Stock Titan
TradingKey - TradingKey
Bone Biologics Corp expected to post a loss of 54 cents a shareEarnings Preview - TradingView
Bone Biologics Corp Stock (BBLG) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):